Companies Vor Biopharma Inc.
Vor Biopharma (VOR): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Vor Biopharma Inc.’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO pay, last three years
- $65,027,569FY2025
CEO total pay was $65,027,569 in fiscal 2025; the brief holds no earlier figure for this CEO.
FY2025: salary $344,615 · bonus $400,000 · stock awards $0 · option awards $64,013,465
Executives and directors
Frequently asked questions
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Jean-Paul Kress | $344,615 | $400,000 | $0 | $64,013,465 | $251,425 | $0 | $18,064 | $65,027,569 |
| President, Chief Executive Officer and Chairman | ||||||||
| Sandesh Mahatme | 217,846 | 274,000 | 35,262,185 | 3,540,099 | 102,996 | 0 | 8,972 | 39,406,098 |
| Chief Financial Officer | ||||||||
| Qing Zuraw | 243,385 | 100,000 | 2,230,250 | 8,570,852 | 0 | 0 | 692,706 | 11,837,193 |
| Former Chief Development Officer | ||||||||
| Robert Ang | 515,026 | 0 | 184,250 | 1,176,895 | 0 | 0 | 1,488,224 | 3,364,395 |
| Former President and Chief Executive Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Jean-Paul Kress | $65,027,569 | — | — | — |
| Sandesh Mahatme | 39,406,098 | — | — | — |
| Qing Zuraw | 11,837,193 | — | — | — |
| Robert Ang | 3,364,395 | 2,220,349 | 2,691,044 | ↑ +1,144,046 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
A core objective of our compensation program is to enable the attraction, retention, and motivation of top talent that will provide us with the expertise and skills necessary to deliver on our short- and long-term goals. We consider compensation for comparable positions at peer companies, historical compensation levels, individual performance, and our desire to motivate employees to achieve short- and long-term results in the best interests of stockholders.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Alpine Rewards, LLC |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
Equity grants and outstanding awards
No plan-based awards are on file for this fiscal year.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Qing Zuraw | RSU | 46,854 | — | $612,850 |
| Robert Ang | Option | 106,332 | 86.02 | — |
| Qing Zuraw | Option | 218,652 | 47.6 | — |
| Sandesh Mahatme | Option | 1,388,274 | 17.8 | — |
| Jean-Paul Kress | Option | 4,164,831 | 17.8 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Erez KalirIndependent · Audit · Partial-year service | $42,033 | — | $81,000 | — | — | $123,033 |
| Alexander (Bo) CumboIndependent · Compensation (Chair) · Nominating and Corporate Governance · Partial-year service | 22,973 | — | 98,392 | — | — | 121,365 |
| Michel DetheuxIndependent · Audit · Partial-year service | 20,958 | — | 98,392 | — | — | 119,350 |
| Sarah ReedIndependent · Departed during FY · Partial-year service | 13,283 | — | 91,925 | — | — | 105,208 |
| Daniella BeckmanIndependent · Lead Independent Director · Audit (Chair) · Compensation | 60,000 | — | 4,200 | — | — | 64,200 |
| Matthew PattersonIndependent · Departed during FY | 53,374 | — | 4,200 | — | — | 57,574 |
| Fouad NamouniIndependent · Compensation · Nominating and Corporate Governance (Chair) · Partial-year service · Newly elected | 46,889 | — | 4,200 | — | — | 51,089 |
| Joshua ResnickIndependent · Departed during FY · Partial-year service | 34,565 | — | 4,200 | — | — | 38,765 |
| David LubnerIndependent · Departed during FY | 31,107 | — | 4,200 | — | — | 35,307 |
| Wouter JoustraIndependent · Partial-year service | 1,522 | — | 30,359 | — | — | 31,881 |
| Andrew LevinIndependent · Partial-year service · Newly elected | 1,522 | — | 30,359 | — | — | 31,881 |
| Sven (Bill) Ante LundbergIndependent · Departed during FY · Partial-year service | 27,310 | — | 4,200 | — | — | 31,510 |
| Robert AngEmployee director · Departed during FY | — | — | — | — | — | 0 |
| Jean-Paul KressEmployee director · Board Chair · Partial-year service | — | — | — | — | — | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | $350,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $355,536 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $355,536 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Vor Biopharma as a peer
Companies that benchmark against VOR
2 companies name VOR as a compensation peer
- Lineage Cell Therapeutics, Inc.LCTXFY2025
- Mersana Therapeutics, Inc.MRSNFY2024
Each company listed discloses VOR in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named VOR in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Vor Biopharma Inc. | 2025 | Jean-Paul Kress | $344,615 | $0 | $64,013,465 | $251,425 | $65,027,569 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Say-on-pay history and pay ratio
No say-on-pay vote is on file for this company.
Insider trades since the proxy
No insider equity transactions reported since the proxy statement.
Sources (21 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Jean-Paul Kress. DEF 14A, filed 2026-04-27. Section “Executive Compensation” · page 35. As printed: 65,027,569. View filing ↗
- Section 01, Sandesh Mahatme. DEF 14A, filed 2026-04-27. Section “Executive Compensation”. As printed: 39,406,098. View filing ↗
- Section 01, Qing Zuraw. DEF 14A, filed 2026-04-27. Section “Executive Compensation”. As printed: 11,837,193. View filing ↗
- Section 01, Robert Ang. DEF 14A, filed 2026-04-27. Section “Executive Compensation”. As printed: 3,364,395. View filing ↗
- Section 08, Erez Kalir. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 123,033. View filing ↗
- Section 08, Alexander (Bo) Cumbo. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 121,365. View filing ↗
- Section 08, Michel Detheux. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 119,350. View filing ↗
- Section 08, Sarah Reed. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 105,208. View filing ↗
- Section 08, Daniella Beckman. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 64,200. View filing ↗
- Section 08, Matthew Patterson. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 57,574. View filing ↗
- Section 08, Fouad Namouni. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 51,089. View filing ↗
- Section 08, Joshua Resnick. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 38,765. View filing ↗
- Section 08, David Lubner. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 35,307. View filing ↗
- Section 08, Wouter Joustra. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 31,881. View filing ↗
- Section 08, Andrew Levin. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 31,881. View filing ↗
- Section 08, Sven (Bill) Ante Lundberg. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 31,510. View filing ↗
- Section 08, Robert Ang. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, Jean-Paul Kress. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 09b board cost (computed). Computed. Cash 355,536 + equity 0 + all other 0 = 355,536, summed across the director compensation table rows.
- Vor Biopharma Inc. (subject), Section 10b CEO total. DEF 14A, filed 2026-04-27. CEO total compensation as printed in Vor Biopharma Inc.'s own proxy. As printed: 65,027,569. View filing ↗